EUCTR2011-005173-23-DE进行中（未招募）不适用
A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Pre-exposure Prophylaxis Schedules to Healthy Adult Subjects
ovartis Vaccines and Diagnostics GmbH0 个研究点目标入组 660 人开始时间: 2012年1月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Males and females between 18 and 65 years of age (inclusive)
- •2.Subjects who have given written consent after the nature of the study has been explained according to local regulatory requirements.
- •3.Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
- •4.Individuals who have access to a touch key telephone and are able to use the eDiary to record safety assessments as required by the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 660
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.History of previous rabies/rabies immune globulin and/or JE immunization.
- •2.Any individuals with a contraindication or precaution against vaccination with Rabipur® or IXIARO® as highlighted in the package inserts of these products
- •3.Subjects currently receiving or planning to receive anti-malarial medications (e.g. Mefloquine) 14 days prior to Day 1 vaccination through Day 43.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Together and/or Separately According to Different Schedules to Healthy SubjectsEUCTR2011-005173-23-ATovartis Vaccines and Diagnostics GmbH660
进行中（未招募）
不适用
Study to evaluate the immunogenicity and safety of GSK Biologicals’ thimerosal-free TIV Flu vaccine versus a licensed comparator in childreEUCTR2015-001258-13-Outside-EU/EEAGlaxoSmithKline Biologicals3,318
进行中（未招募）
不适用
A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Tdap Vaccine GSK Boostrix and Chiron Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Boostrix, Or One Dose of Chiron Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years - NDEUCTR2005-005519-12-ITCHIRO1,000
进行中（未招募）
1 期
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab( IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaClaudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaMedDRA version: 20.0Level: PTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002567-17-BEAstellas Pharma Global Development, Inc. (APGD)550
进行中（未招募）
1 期
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaClaudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric orGastroesophageal Junction (GEJ) AdenocarcinomaMedDRA version: 20.0Level: PTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000519-26-GRAstellas Pharma Global Development, Inc. (APGD)500